West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Last trade$414.98
Day change-$2.8225 (-0.68%)
Day range$402.07 – $420.25
Volume208,133
Market cap$29.10B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$29.1B
Price / earnings
45.55×
Price / book
9.81×
Price / sales
8.57×
EV / sales
8.49×
EV / EBITDA
30.41×
Profitability
Earnings per share
$9.17
Return on assets
15.73%
Return on equity
21.52%
Dividend yield
0.22%
Liquidity and leverage
Debt / equity
0.07×
Current ratio
2.82×
Quick ratio
2.1×
Cash ratio
0.72×
Cash flow
Price / cash flow
44.47×
Price / free cash flow
64.19×
Free cash flow
$453.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for WST, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$874.5M
$872.3M
$844.9M
$805M
$804.6M
$766.5M
$698M
$748.8M
Cost of revenue
$527.1M
$543.1M
$548.5M
$501.1M
$510.3M
$492.6M
$466.1M
$475.2M
Gross profit
$347.4M
$329.2M
$296.4M
$303.9M
$294.3M
$273.9M
$231.9M
$273.6M
Selling, general and administrative
$112.9M
$117.6M
$99.5M
$107M
$102.7M
$95.9M
$88M
$85.3M
Research and development
$18.3M
$19.7M
$15.8M
$21.8M
$17.1M
$19.1M
$16.3M
$18.5M
Total operating expenses
$131.2M
$137.3M
$115.3M
$128.8M
$119.8M
$115M
$104.3M
$103.8M
Operating income
$216.2M
$191.9M
$181.1M
$175.1M
$174.5M
$158.9M
$127.6M
$169.8M
Interest expense
-$3.8M
-$2.6M
-$1.9M
$200K
-$200K
-$100K
-$400K
$800K
Income before taxes
$272M
$186.2M
$180.1M
$161.5M
$174M
$162M
$110.5M
$164.9M
Income taxes
$58M
$32.2M
$44.7M
$33.3M
$34M
$30.2M
$24.1M
$36.8M
Net income
$214M
$154M
$138.8M
$132.1M
$140M
$131.8M
$89.8M
$130.1M
Net income attributable to common shareholders
$214M
$154M
$138.8M
$132.1M
$140M
$131.8M
$89.8M
$130.1M
EBITDA
$262.1M
$238.1M
$226.3M
$222.1M
$217.5M
$200.3M
$167.6M
$210.5M
Basic earnings per share
$3.04
$2.17
$1.93
$1.83
$1.94
$1.82
$1.24
$1.79
Diluted earnings per share
$3.02
$2.15
$1.92
$1.82
$1.92
$1.82
$1.23
$1.77
Recent news
Company coverage with links to the original publishers.
GE HealthCare Technologies (GEHC) is well-positioned for growth with a record $23.7 billion backlog (up 12%), strong Pharmaceutical Diagnostics revenue growth, and raised 2026 guidance. However, persistent component inflation, tariff uncertainty, and China's fragile recovery pose risks to margin expansion.
Doximity announced an expansion of its AI-powered clinical tools partnership with NewYork-Presbyterian, Columbia University, and Weill Cornell Medicine. The collaboration includes Doximity Ask (clinical decision support integrated with Epic EHR) and Doximity Scribe (patient documentation and dictation). The company also launched DoseCheck, a safety feature reducing dosing errors by over 99%. Despite the positive developments, DOCS stock has declined 24.7% year-to-date.
Koninklijke Philips reported strong equipment order intake growth of 8% with Diagnosis & Treatment orders surging nearly 20%, and Personal Health sales rising 8%. However, ultrasound manufacturing delays, China's pricing pressure from centralized procurement, and inflation concerns pose significant risks to profitability and growth trajectory. The company maintains a Zacks Rank #3 (Hold) rating.
GE HealthCare Technologies announced the formation of the MAGNUS Neuro Alliance, a collaborative research network using its head-only 3.0T MR system to advance neuroscience research. The alliance will unite leading institutions for multi-site trials and research focused on developing MRI-based biomarkers for neurological diseases. GEHC stock declined 2.2% following the announcement, though the initiative could strengthen the company's position in advanced imaging and create long-term growth opportunities.
AngioDynamics (ANGO) is gaining momentum from strong NanoKnife platform performance, with revenues surging 29% to $8.3 million in fiscal Q1 2027, driven by rising prostate procedure volumes and expanded regulatory approvals. The company's Med Tech segment continues robust growth with 13.2% year-over-year revenue increase, and management expects 12%-15% Med Tech revenue growth in fiscal 2027. However, tariffs and inflation remain headwinds despite recent tariff refunds improving margins.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 10, 2026
$0.26
Nov 18, 2026
recurring
Jul 29, 2026
$0.22
Aug 5, 2026
recurring
Apr 29, 2026
$0.22
May 6, 2026
recurring
Jan 28, 2026
$0.22
Feb 4, 2026
recurring
Nov 12, 2025
$0.22
Nov 19, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.